Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.

Journal:

Diabetes Care

Published:

2025-06-22

DOI:

10.2337/dc25-1082

Affiliations:

11

Authors:

10

Go to article

Institutions	Authors	Share
Novo Nordisk, Denmark	2.000000	0.20
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)	2.000000	0.20
Klinik Landstrasse, Austria	1.000000	0.10
Novo Nordisk India, India	1.000000	0.10
University of Gothenburg (GU), Sweden	1.000000	0.10
Medical University of Graz (Med Uni Graz), Austria	1.000000	0.10
Lillebaelt Hospital, Denmark	0.500000	0.05
University of Southern Denmark (SDU), Denmark	0.500000	0.05
St. Michael's Hospital, Canada	0.500000	0.05
University of Toronto (U of T), Canada	0.500000	0.05

Interested in Clinical Sciences?